Anti-cancer immunotherapy using cancer-derived multiple epitope-peptides cocktail vaccination clinical studies in patients with refractory/persistent disease of uterine cervical cancer and ovarian cancer [phase 2]

References

• Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, O’Day SJ, Hoos A, Humphrey R, Berman DM, Long berg N, Korman AJ. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci. 2013;1291(1):1–13.
   Google Scholar
• Koppolu V, Rekha Vasigala VK. Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma. J Cancer Res Ther. 2018;14(6):1167–1175.
   PubMed Web of Science ®Google Scholar
• Coleman R, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–16. doi:10.1056/NEJMoa1503093.
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2015;33(34):4015–4022. doi:10.1200/JCO.2015.62.3397.
   PubMed Web of Science ®Google Scholar
• Matulonis AU, Shapira-Frommer R, Santin A, Lisyanskaya SA, Pignata S, Vergote I, Raspagliesi F, Sonke GS, Birrer M, Provencher DM, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: interim results from the phase 2 KEYNOTE-100 study. J Clin Oncol. 2018;36(15_suppl):5511. ASCO 2018 Procedings. doi:10.1200/JCO.2018.36.15_suppl.5511.
   Web of Science ®Google Scholar
• Omatsu K, Hamanishi J, Katsumata N, Nishio S, Sawada K, Takeuchi S, Aoki D, Fujiwara K, Sugiyama T, Konishi I. Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patinets with platinum-resistant (advanced or recurrent) ovarian cancer: open-label, randomized trial in Japan (NINJA trial). Ann Oncol. 2020:8070. ESMO2020 procedings. https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/session/list?q=Omatsu
   Google Scholar
• Suda T, Tsunoda T, Daigo Y, Nakamura Y, Tahara H. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci. 2007;98(11):1803–1808. doi:10.1111/j.1349-7006.2007.00603.x.
   PubMed Web of Science ®Google Scholar
• Suda T, Tsunoda T, Uchida N, Watanabe T, Hasegawa S, Satoh S, Ohgi S, Furukawa Y, Nakamura Y, Tahara H, et al. Identification of secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarray. Cancer Sci. 2006;97(5):411–419. doi:10.1111/j.1349-7006.2006.00194.x.
   PubMed Web of Science ®Google Scholar
• Masuzawa T, Fujiwara Y, Okada K, Nakamura A, Takiguchi S, Nakajima K, MIYATA H, YAMASAKI M, KUROKAWA Y, OSAWA R, et al. Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Int J Oncol. 2012;41(4):1297–1304. doi:10.3892/ijo.2012.1573.
   PubMed Web of Science ®Google Scholar
• Yamaue H, Tsunoda T, Tani M, Miyazawa M, Yamao K, Mizuno N, Okusaka T, Ueno H, Boku N, Fukutomi A, et al. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC study. Cancer Sci. 2015;106(7):883–890. doi:10.1111/cas.12674.
   PubMed Web of Science ®Google Scholar
• Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tsunoda T, Nakatsuru S, et al. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers. Clin Cancer Res. 2008;14(20):6487–6495. doi:10.1158/1078-0432.CCR-08-1086.
   PubMed Web of Science ®Google Scholar
• Asahara S, Takeda K, Yamao K, Maguchi H, Yamaue H. Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer. J Transl Med. 2013;11(1):291. doi:10.1186/1479-5876-11-291.
   PubMedGoogle Scholar
• Kono K, Mizukami Y, Daigo Y, Takano A, Masuda K, Yoshida K, Tsunoda T, Kawaguchi Y, Nakamura Y, Fujii H, et al. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci. 2009;100(8):1502–1509. doi:10.1111/j.1349-7006.2009.01200.x.
   PubMed Web of Science ®Google Scholar
• Yoshitake Y, Nishimura Y, Nakamura Y, Shinohara M. A clinical trial of multiple peptides vaccination for advanced head and neck cancer patients induced immune responses and prolonged OS. Oncoimmunology. 2015;4(8):e1022307. doi:10.1080/2162402X.2015.1022307.
   PubMed Web of Science ®Google Scholar
• Takeuchi S, Shoji T, Kagabu M, Honda T, Nagasawa T, Nitta Y, Sugiyama T, Yoshimura S, Nakamura Y. Anti-cancer immunotherapy epitope-peptides vaccination in patients with refractory/persistent disease of cervical cancer and ovarian cancer (phase 1 studies). Cancer Res J. 2019;7(3):106–116. doi:10.11648/j.crj.20190703.15.
   Google Scholar
• Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–7420. doi:10.1158/1078-0432.CCR-09-1624.
   PubMed Web of Science ®Google Scholar
• Ishikawa N, Takano A, Yasui W, Inai K, Nishimura H, Ito H, Miyagi Y, Nakayama H, Fujita M, Hosokawa M, et al. Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res. 2007;67(24):11601–11611. doi:10.1158/0008-5472.CAN-07-3243.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Fukuhara M, Yamaura T, Mutoh S, Okabe N, Yaginuma H, Hasegawa T, Yonechi A, Osugi J, Hoshino M, et al. Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer. J Transl Med. 2013;11(1):97. doi:10.1186/1479-5876-11-97.
   PubMed Web of Science ®Google Scholar
• Fujiwara Y, Okada K, Omori T, Sugimura K, Miyata H, Ohue M, Kobayashi S, Takahashi H, Nakano H, Mochizuki C, et al. Multiple therapeutic peptide vaccines for patients with advanced gastric cancer. Int J Oncol. 2017;50(5):1655–1662. doi:10.3892/ijo.2017.3955.
   PubMed Web of Science ®Google Scholar
• Iinuma H, Fukushima R, Inaba T, Tamura J, Inoue T, Ogawa E, Horikawa M, Ikeda Y, Matsutani N, Takeda K, et al. Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients. J Transl Med. 2014;12(1):84. doi:10.1186/1479-5876-12-84.
   PubMedGoogle Scholar
• Togashi A, Katagiri T, Ashida S, Fujioka T, Maruyama O, Wakumoto Y, Sakamoto Y, Fujime M, Kawachi Y, Shuin T, et al. Hypoxia-inducible protein 2 (HIG2), a novel diagnostic marker for renal cell carcinoma and potential target for molecular therapy. Cancer Res. 2005;65(11):4817–4826. doi:10.1158/0008-5472.CAN-05-0120.
   PubMed Web of Science ®Google Scholar
• Nishimura S, Tsuda H, Ito K, Takano M, Terai Y, Jobo T, Kigawa J, Sugiyama T, Yaegashi N, Aoki D, et al. Differential expression of hypoxia-inducible protein 2 among different histological types of epithelial OC and in clear cell adenocarcinomas. Int J Gynecol Cancer. 2010;20(2):220–226. doi:10.1111/IGC.0b013e3181ca1e16.
   PubMed Web of Science ®Google Scholar
• Seo T, Konda R, Sugimura J, Iwasaki K, Nakamura Y, Fujioka T. Expression of hypoxia-inducible protein 2 in renal cell carcinoma: A promising candidate for molecular targeting therapy. Oncol Lett. 2010;1(4):697–701. doi:10.3892/ol_00000122.
   PubMed Web of Science ®Google Scholar
• Nishimura S, Tsuda H, Nomura H, Kataoka F, Chiyoda T, Tanaka H, Tanaka K, Susumu N, Aoki D. Expression of hypoxia-inducible 2 (HIG2) protein in uterine cancer. Eur J Gynaecol Oncol. 2011;32(2):146–149.
   PubMed Web of Science ®Google Scholar
• Yokomine K, Senju S, Nakatsura T, Irie A, Hayashida Y, Ikuta Y, Harao M, Imai K, Baba H, Iwase H, et al. The forkhead box M1 transcription factor as a candidate of target for anti-cancer immunotherapy. Int J Cancer. 2010;123(9):2153–2163.
   Google Scholar
• Yang H, Wen L, Wen M, Liu T, Zhao L, Wu B, Yun Y, Liu W, Wang H, Wang Y, et al. FoxM1 promotes epithelial-mesenchymal transition, invasion, and migration of tongue squamous cell carcinoma cells through a c-Met/AKT-dependent positive feedback loop. Anticancer Drugs. 2018;29(3):216–226. doi:10.1097/CAD.0000000000000585.
   PubMed Web of Science ®Google Scholar
• Chen H, Zou Y, Yang H, Wang J, Pan H. Downregulation of FoxM1 inhibits proliferation, invasion, and angiogenesis of HeLa cells in vitro and in vivo. Int J Oncol. 2014;45(6):2355–2364. doi:10.3892/ijo.2014.2645.
   PubMed Web of Science ®Google Scholar
• Halasi M, Gartel AL. Targeting FOXM1 in cancer. Biochem Pharmacol. 2013;85(5):644–652. doi:10.1016/j.bcp.2012.10.013.
   PubMed Web of Science ®Google Scholar
• Gu C, Banasavadi-Siddegowda YK, Joshi K, Nakamura Y, Kurt H, Gupta S, Nakano I. Tumor-specific activation of the C-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner. Stem Cell. 2013;31(5):870–881. doi:10.1002/stem.1322.
   PubMed Web of Science ®Google Scholar
• Minata M, Gu C, Joshi K, Nakano-Okuno M, Hong C, Nguyen CH, Kornblum HI, Molla A, Nakano I. Multi-kinase inhibitor C1 triggers mitotic catastrophe of glioma stem cells mainly through MELK kinase inhibition. PLoS One. 2014;9(4):e92546. doi:10.1371/journal.pone.0092546.
   PubMed Web of Science ®Google Scholar
• Kim SH, Joshi K, Ezhilarasan R, Myers TR, Siu J, Gu C, Nakano-Okuno M, Taylor D, Minata M, Sulman E, et al. EZH2 protects glioma stem cells from radiation-induced cell death in a MELK/FOXM1-dependent manner. Stem Cell Rep. 2015;4(2):226–238. doi:10.1016/j.stemcr.2014.12.006.
   PubMed Web of Science ®Google Scholar
• Cheng J, Qin B, Liu B, Huang T, Li Y, Ma L. Maternal embryonic leucine zipper kinase inhibits epithelial-mesenchymal transition by regulating transforming growth factor-β signaling. Oncol Lett. 2017;13(6):4794–4798. doi:10.3892/ol.2017.6081.
   PubMed Web of Science ®Google Scholar
• Janostiak R, Rauniyar N, Lam TT, Ou J, Zhu LJ, Green MR, Wajapeyee N. MELK promotes melanoma growth by stimulating the NF-κB pathway. Cell Rep. 2017;21(10):2829–2841. doi:10.1016/j.celrep.2017.11.033.
   PubMed Web of Science ®Google Scholar
• Kohler RS, Kettelhack H, Knipprath-Mészaros AM, Fedier A, Schoetzau A, Jacob F, Heinzelmann-Schwarz V. MELK expression in OC correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of OC cells. Gynecol Oncol. 2017;145(1):159–166. doi:10.1016/j.ygyno.2017.02.016.
   PubMed Web of Science ®Google Scholar
• Kato T, Sato N, Hayama S, Yamabuki T, Ito T, Miyamoto M, Kondo S, Nakamura Y, Daigo Y. Activation of Holliday junction recognizing protein involved in the chromosomal stability and immortality of cancer cells. Cancer Res. 2007;67(18):8544–8553. doi:10.1158/0008-5472.CAN-07-1307.
   PubMed Web of Science ®Google Scholar
• Bassett EA, DeNizio J, Barnhart-Dailey MC, Panchenko T, Sekulic N, Rogers DJ, Foltz DR, Black B. HJURP uses distinct CENP-A surfaces to recognize and to stabilize CENP-A/histone H4 for centromere assembly. Dev Cell. 2012;22(4):749–762. doi:10.1016/j.devcel.2012.02.001.
   PubMed Web of Science ®Google Scholar
• Heo JI, Cho JH, Kim JR. HJURP regulates cellular senescence in human fibroblasts and endothelial cells via a p53-dependent pathway. J Gerontol A Biol Sci Med Sci. 2013;68(8):914–925. doi:10.1093/gerona/gls257.
   PubMed Web of Science ®Google Scholar
• Stankovic A, Guo LY, Mata JF, Bodor DL, Cao XJ, Bailey AO, Shabanowitz J, Hunt DF, Garcia BA, Black BE, et al. A dual inhibitory mechanism sufficient to maintain cell-cycle-restricted CENP-A assembly. Mol Cell. 2017;65(2):231–246. doi:10.1016/j.molcel.2016.11.021.
   PubMed Web of Science ®Google Scholar
• Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonopavde G, Knox JJ, Tran B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):124
   Google Scholar
• Wang Q, Ma J, Jiang Z, Ming L. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in acute pulmonary embolism: a systematic review and meta-analysis. Int Angiol. 2018;37(1):4–11
   Google Scholar
• Hasegawa K, Ikeda Y, Kunugi Y, Kurosaki A, Imai Y, Kohyama S, Nagao S, Kozawa E, Yoshida K, Tsunoda T, et al. Phase I study of multiple epitope peptide vaccination in patients with recurrent or persistent CC. J Immunother. 2018;41(4):201–207. doi:10.1097/CJI.0000000000000214.
   PubMed Web of Science ®Google Scholar
• Takeuchi S. Biology and treatment of cervical adenocarcinoma. Chin J Cancer Res. 2016;28(2):254–262. doi:10.21147/j.issn.1000-9604.2016.02.11.
   PubMed Web of Science ®Google Scholar
• Derer A, Spiljar M, Baumler M, Hecht M, Fietkau R, Frey B, et al. Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells. Front Immunol. 2016;7:610. doi:10.3389/fimmu.2016.00610.
   PubMed Web of Science ®Google Scholar